Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $190.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price target boosted by Royal Bank Of Canada from $187.00 to $190.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also weighed in on NBIX. Weiss Ratings upgraded Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 14th. Cantor Fitzgerald upped their price target on Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. BMO Capital Markets decreased their price target on Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating for the company in a report on Monday, October 12th. Piper Sandler increased their price target on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Wells Fargo & Company raised their price objective on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $202.32.

Neurocrine Biosciences Price Performance

NBIX opened at $159.76 on Tuesday. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The firm has a market capitalization of $16.17 billion, a PE ratio of 20.81, a P/E/G ratio of 0.74 and a beta of 0.36. The company’s 50-day moving average is $147.04 and its 200 day moving average is $147.90.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The company’s quarterly revenue was up 41.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.04 EPS. As a group, analysts expect that Neurocrine Biosciences will post 7.66 EPS for the current year.

Insider Activity at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the sale, the chief financial officer directly owned 42,808 shares in the company, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David Boyer sold 826 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the completion of the transaction, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. This represents a 8.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 18,137 shares of company stock valued at $2,829,332. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in NBIX. Entrust Financial LLC increased its holdings in Neurocrine Biosciences by 62.9% during the third quarter. Entrust Financial LLC now owns 202 shares of the company’s stock worth $29,000 after buying an additional 78 shares during the last quarter. Basecamp Wealth Advisors LLC boosted its stake in Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares during the last quarter. Raleigh Capital Management Inc. boosted its stake in Neurocrine Biosciences by 561.8% in the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock valued at $32,000 after acquiring an additional 191 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in Neurocrine Biosciences in the first quarter valued at about $33,000. Finally, Ascentis Independent Advisors bought a new position in shares of Neurocrine Biosciences during the 1st quarter valued at approximately $40,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
• Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
• Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
• Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.